- Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
- Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
- Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Key statistics
As of last trade Nuvalent Inc (NUVL:NSQ) traded at 71.57, -19.94% below its 52-week high of 89.39, set on Mar 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 72.67 |
---|---|
High | 73.54 |
Low | 71.31 |
Bid | 71.50 |
Offer | 71.73 |
Previous close | 73.00 |
Average volume | 470.49k |
---|---|
Shares outstanding | 64.56m |
Free float | 54.51m |
P/E (TTM) | -- |
Market cap | 4.71bn USD |
EPS (TTM) | -2.41 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 16:11 BST.
More ▼